Celcuity Inc. (CELC)Healthcare | Biotechnology | Minneapolis, United States | NasdaqCM
122.46 USD
-2.79
(-2.228%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 122.46 Short-term: ★★★★★ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:12 a.m. EDT
Celcuity (CELC) is in a distinct 'boom' phase driven by credible clinical data and institutional accumulation; the options market is pricing in a massive move above $125 with $150 being the consensus short-term resistance target, though the company's negative cash flow and dilution risk make this a high-volatility momentum play suitable for trading, not a long-term equity hold. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.050633 |
| AutoETS | 0.056834 |
| AutoTheta | 0.107000 |
| AutoARIMA | 0.269609 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.547 |
| Excess Kurtosis | -0.34 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 320.128 |
| Market Cap | 5,919,309,312 |
| Forward P/E | -111.33 |
| Beta | 0.42 |
| Website | https://www.celcuity.com |
As of April 19, 2026, 12:12 a.m. EDT: Options speculators are aggressively positioning for upside continuation. May 15 and June 18 call data reveal massive 'OI walls' at 150 and 155 strikes, representing significant resistance and potential target zones. Deep out-of-the-money OTM call volume at 155 strikes suggests high-conviction momentum plays. Conversely, put activity is concentrated in the downside (65-95 strikes), with notable new flow at the 115 strike (Vol 177 > OI 5), likely acting as a hedging threshold or insurance against a drop below recent lows, rather than a bearish signal. The Call/Put ratio heavily favors bullish sentiment across approaching expirations.
| Attribute | Value |
|---|---|
| 52 Week Change | 10.71866 |
| Address1 | 16,305 36th Avenue North |
| Address2 | Suite 100 |
| All Time High | 127.34 |
| All Time Low | 4.03 |
| Ask | 123.06 |
| Ask Size | 9 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 730,790 |
| Average Daily Volume3 Month | 741,662 |
| Average Volume | 741,662 |
| Average Volume10Days | 730,790 |
| Beta | 0.422 |
| Bid | 121.84 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 2.084 |
| City | Minneapolis |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 122.46 |
| Current Ratio | 10.547 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 125.66 |
| Day Low | 121.46 |
| Debt To Equity | 320.128 |
| Display Name | Celcuity |
| Earnings Call Timestamp End | 1,774,470,600 |
| Earnings Call Timestamp Start | 1,774,470,600 |
| Earnings Timestamp | 1,774,468,800 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -172,024,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -33.714 |
| Enterprise Value | 5,799,717,376 |
| Eps Current Year | -3.78 |
| Eps Forward | -1.1 |
| Eps Trailing Twelve Months | -3.78 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 111.6228 |
| Fifty Day Average Change | 10.837196 |
| Fifty Day Average Change Percent | 0.09708766 |
| Fifty Two Week Change Percent | 1,071.8661 |
| Fifty Two Week High | 127.34 |
| Fifty Two Week High Change | -4.8799973 |
| Fifty Two Week High Change Percent | -0.03832258 |
| Fifty Two Week Low | 9.51 |
| Fifty Two Week Low Change | 112.95 |
| Fifty Two Week Low Change Percent | 11.876971 |
| Fifty Two Week Range | 9.51 - 127.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 29,656,484 |
| Forward Eps | -1.1 |
| Forward P E | -111.32727 |
| Free Cashflow | -96,047,504 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 155 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.102060005 |
| Held Percent Institutions | 0.98135 |
| Implied Shares Outstanding | 48,336,675 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota. |
| Long Name | Celcuity Inc. |
| Market | us_market |
| Market Cap | 5,919,309,312 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_254573983 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -177,042,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,919,309,220 |
| Number Of Analyst Opinions | 10 |
| Open | 125.66 |
| Operating Cashflow | -153,280,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 763 392 0767 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 122.46 |
| Post Market Time | 1,776,460,830 |
| Previous Close | 125.25 |
| Price Eps Current Year | -32.396824 |
| Price Hint | 2 |
| Price To Book | 58.761993 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.999 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.27273 |
| Region | US |
| Regular Market Change | -2.79 |
| Regular Market Change Percent | -2.22755 |
| Regular Market Day High | 125.66 |
| Regular Market Day Low | 121.46 |
| Regular Market Day Range | 121.46 - 125.66 |
| Regular Market Open | 125.66 |
| Regular Market Previous Close | 125.25 |
| Regular Market Price | 122.46 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 471,814 |
| Return On Assets | -0.30244 |
| Return On Equity | -1.6379601 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 48,336,675 |
| Shares Percent Shares Out | 0.1821 |
| Shares Short | 8,799,830 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,108,952 |
| Short Name | Celcuity Inc. |
| Short Percent Of Float | 0.2748 |
| Short Ratio | 12.8 |
| Source Interval | 15 |
| State | MN |
| Symbol | CELC |
| Target High Price | 155.0 |
| Target Low Price | 94.0 |
| Target Mean Price | 128.6 |
| Target Median Price | 125.5 |
| Total Cash | 441,496,992 |
| Total Cash Per Share | 9.134 |
| Total Debt | 321,904,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 79.4409 |
| Two Hundred Day Average Change | 43.019096 |
| Two Hundred Day Average Change Percent | 0.5415233 |
| Type Disp | Equity |
| Volume | 471,814 |
| Website | https://www.celcuity.com |
| Zip | 55,446 |